EBS News and Press, Emergent Biosolutions Inc. From 04/30/21

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Emergent BioSolutions Inc. 2021 Q1 - Results - Earnings Call Presentation

Next week, for the first time since the week of April 12, the CDC will allocate doses of Johnson & Johnson's (JNJ) COVID-19 vaccine to states.For the week of May 3, the CDC is allocating 765.5K doses. By comparison, it allocated 700K doses the week of April 12, just before administration ...

Image source: The Motley Fool. Emergent BioSolutions Inc (NYSE: EBS) Q1 2021 Earnings Call Apr 29, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript

Emergent BioSolutions, Inc. (EBS) Q1 2021 Earnings Conference Call April 29, 2021 5:00 PM ET Company Participants Robert Burrows - VP, IR Robert Kramer - CEO, President & Executive Director Richard Lindahl - EVP, CFO & Treasurer Adam Havey - EVP, Business Operations Conference Call Pa...

Emergent Biosolutions (EBS): Q1 Non-GAAP EPS of $1.53 beats by $0.36; GAAP EPS of $1.28 beats by $0.49.Revenue of $343M (+78.2% Y/Y) misses by $16.69M.For Q2 2021, the Company expects total revenues of $370 million to $430 million vs. $504.63M consensusShares -5%.Press Release For further d...

Emergent BioSolutions (EBS) has 60M doses of Johnson & Johnson's (JNJ) COVID-10 ready to distribute as soon as the FDA gives authorization to release it, Bloomberg reports.Vaccine production at the company's key Baltimore production facility has been stalled since mid-April as the FDA con...

Emergent Biosolutions (NYSE:EBS) is scheduled to announce Q1 earnings results on Thursday, April 29th, after market close.The consensus EPS Estimate is $1.17 and the consensus Revenue Estimate is $359.69M (+86.9% Y/Y).Over the last 2 years, EBS has beaten EPS estimates 88% of the time an...

Emergent BioSolutions ' (NYSE: EBS) streak as a hot coronavirus stock recently came to an abrupt end, after the company ran into problems with its coronavirus vaccine manufacturing contracts. In a little over two months, it is down nearly 50% from its February highs. W...

Boston, Massachusetts--(Newsfile Corp. - April 26, 2021) - Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact...

Shares of Emergent BioSolutions (NYSE: EBS) were falling 4% as of 11:07 a.m. EDT on Thursday after sinking as much as 7.6% earlier in the day. The stock tumbled earlier this week after the company was forced to halt production at its Bayview facility in Baltimore, Maryland, ...